State of Alaska Department of Revenue Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA)

State of Alaska Department of Revenue reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 9.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 62,498 shares of the company’s stock after selling 6,755 shares during the quarter. State of Alaska Department of Revenue’s holdings in Moderna were worth $6,658,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Quadrant Capital Group LLC lifted its stake in Moderna by 7.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock worth $266,000 after acquiring an additional 187 shares during the period. International Assets Investment Management LLC lifted its position in shares of Moderna by 6,528.9% in the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after purchasing an additional 381,808 shares during the period. abrdn plc boosted its stake in shares of Moderna by 477.5% during the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after purchasing an additional 399,843 shares in the last quarter. Ontario Teachers Pension Plan Board purchased a new position in Moderna during the fourth quarter valued at approximately $1,358,000. Finally, Hobbs Group Advisors LLC bought a new position in Moderna in the fourth quarter worth approximately $664,000. 75.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MRNA has been the topic of several recent research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Friday, June 28th. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research report on Thursday, June 27th. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. William Blair reissued a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Finally, Piper Sandler reissued an “overweight” rating and issued a $214.00 price objective on shares of Moderna in a research report on Thursday, June 27th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $134.02.

Moderna Stock Performance

Moderna stock traded down $1.12 during mid-day trading on Wednesday, hitting $115.95. The company had a trading volume of 1,851,589 shares, compared to its average volume of 4,179,948. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average is $134.68 and its 200-day moving average is $112.65. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47. The company has a market capitalization of $44.44 billion, a price-to-earnings ratio of -7.40 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter in the previous year, the company earned $0.19 earnings per share. The firm’s revenue for the quarter was down 91.0% on a year-over-year basis. Equities research analysts predict that Moderna, Inc. will post -7.46 EPS for the current year.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 705 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $101.93, for a total value of $71,860.65. Following the sale, the chief financial officer now directly owns 5,048 shares of the company’s stock, valued at $514,542.64. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Moderna news, President Stephen Hoge sold 255 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $120.96, for a total transaction of $30,844.80. Following the completion of the transaction, the president now owns 1,486,508 shares of the company’s stock, valued at $179,808,007.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 705 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $101.93, for a total value of $71,860.65. Following the completion of the transaction, the chief financial officer now owns 5,048 shares in the company, valued at approximately $514,542.64. The disclosure for this sale can be found here. Insiders sold a total of 396,255 shares of company stock worth $54,593,731 in the last 90 days. Corporate insiders own 15.20% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.